Page last updated: 2024-08-16

sb 206553 and oxidopamine

sb 206553 has been researched along with oxidopamine in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brotchie, JM; Fox, SH; Moser, B1
Brotchie, JM; Fox, SH1

Other Studies

2 other study(ies) available for sb 206553 and oxidopamine

ArticleYear
Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Experimental neurology, 1998, Volume: 151, Issue:1

    Topics: Animals; Behavior, Animal; Disease Models, Animal; Dopamine Agonists; Excitatory Amino Acid Antagonists; Indoles; Kynurenic Acid; Locomotion; Male; Microinjections; Oxidopamine; Parkinson Disease, Secondary; Pyridines; Quinpirole; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Serotonin Antagonists; Substantia Nigra; Sympatholytics; Urea

1998
5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat.
    European journal of pharmacology, 2000, Jun-09, Volume: 398, Issue:1

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Disease Models, Animal; Dopamine Agonists; Indoles; Levodopa; Locomotion; Male; Oxidopamine; Parkinson Disease, Secondary; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2C; Receptors, Dopamine D1; Receptors, Serotonin; Serotonin Antagonists

2000